ScholarIQanswers from OpenAlex
Hidradenitis Suppurativa and Treatments
TopicLeading institutions, researchers & key papers
Hidradenitis Suppurativa and Treatments is a topic indexed in ScholarIQ from OpenAlex.
What is known about Hidradenitis Suppurativa and Treatments?
ScholarIQrecord summary
This cluster of papers focuses on the treatment, pathogenesis, and comorbidities of Hidradenitis Suppurativa (HS), also known as Acne Inversa. It covers topics such as inflammatory pathways, genetic susceptibility, metabolic syndrome, and the impact of HS on quality of life. The cluster also discusses various therapeutic approaches including immunosuppressive therapy and TNF-alpha inhibitors.
How many works does Hidradenitis Suppurativa and Treatments have?
ScholarIQindexed works
Hidradenitis Suppurativa and Treatments has 86 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Hidradenitis Suppurativa and Treatments?
ScholarIQopenalex
The OpenAlex for Hidradenitis Suppurativa and Treatments is on the source record.
What are the most-cited papers on Hidradenitis Suppurativa and Treatments?
ScholarIQmost cited works
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B. Kimball, Martin M. Okun, David Williams, Alice B. Gottlieb, Kim Papp, Christos C. Zouboulis, April W. Armstrong, Francisco A. Kerdel, Michael H. Gold, Seth Forman, Neil J. Korman, Evangelos J. Giamarellos‐Bourboulis, Jeffrey Crowley, Charles Lynde, Z. Reguiaï, Errol-Prospero Prens, Eihab Alwawi, Nael M. Mostafa, Brett Pinsky, Murali Sundaram, Yihua Gu, Dawn M. Carlson, Gregor B. E. Jemec
Hidradenitis suppurativa
Robert Sabat, Gregor B. E. Jemec, Łukasz Matusiak, Alexa B. Kimball, Errol P. Prens, Kerstin Wolk
Hidradenitis suppurativa
Samantha R. Goldburg, Bruce Strober, Michael Payette
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity
Christos C. Zouboulis, Thrasyvoulos Tzellos, Αthanassios Kyrgidis, Gregor B. E. Jemec, Falk G. Bechara, Evangelos J. Giamarellos‐Bourboulis, John R Ingram, Theodora Kanni, Ioannis Karagiannidis, Antonio Martorell, Łukasz Matusiak, Andreas Pinter, Errol P. Prens, Dagmar Presser, Sylke Schneider‐Burrus, Esther von Stebut, Jacek C. Szepietowski, Hessel H. van der Zee, Sophia Wilden, Robert Sabat, Rodney Sinclair, Dunja Ana Vekic, P. De Haes, V. del Mármol, Afsáneh Alavi, Wayne Gulliver, Aude Nassif, Georgios Nikolakis, Maurizio Podda, C. Antoniou, Florentina Delli, Clio Dessinioti, Aikaterini Patsatsi, Anastasia Trigoni, C. Zisimou, Vincenzo Bettoli, Simone Garcovich, Jurr Boer, Barbara Horváth, G. Ingvarsson, L. Puig, Robert E. Hunger, Lennart Emtestam, F. William Danby, Alexa B. Kimball
Diagnostic delay in hidradenitis suppurativa is a global problem
Ditte Marie Lindhardt Saunte, Jurr Boer, Alexander Stratigos, Jacek C. Szepietowski, Iltefat Hamzavi, K.H. Kim, Kian Zarchi, C. Antoniou, Łukasz Matusiak, Henry W. Lim, Melissa Williams, Hayoung Kwon, MA Gürer, F. Mammadova, A Kaminsky, Errol P. Prens, Hessel H. van der Zee, Vincenzo Bettoli, Stefania Zauli, Jürg Hafner, Severin Läuchli, Lars E. French, Hassan Riad, Moetaz El‐Domyati, Hossam Abdel‐Wahab, Brian Kirby, G. Kelly, Perla Calderón, V. del Mármol, Farida Benhadou, J. Revuz, Christos C. Zouboulis, Ioannis Karagiannidis, Karin Sartorius, Lena Hagströmer, Erin McMeniman, Nicholas Wei Xun Ong, Mateja Dolenc‐Voljč, Zrinka Bukvić Mokoš, Luca Borradori, Robert E. Hunger, Christopher Sladden, Noah Scheinfeld, Nayera Moftah, Lennart Emtestam, Jan Lapins, N. Doss, Ichiro Kurokawa, Gregor B. E. Jemec
Where is Hidradenitis Suppurativa and Treatments research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Hidradenitis Suppurativa and Treatments is open access?
ScholarIQopen access share
53%OPEN ACCESS